Biome Australia sells clinically validated probiotics through pharmacies and health practitioners, having just reported its first profitable year with $18.4 million in revenue. At A$0.43 versus our fair value of A$0.229, the stock is overvalued by 88%. The core problem is simple: even our most optimistic scenario puts the stock at A$0.385 — still below today's price — meaning the market has priced in an outcome better than best case.

The closest fit for BIO at current levels is the growth investor with a high risk tolerance and a multi-year horizon — but only after a meaningful price correction. The revenue trajectory is compelling, the clinical moat is differentiating, and the international expansion is early enough to surprise on the upside. What growth investors must weigh carefully is that the market has already priced this optimism in full.

Biome Australia sells premium, clinically validated probiotic products through pharmacists and health practitioners across Australia, and increasingly through distribution partners in Ireland, Canada, and New Zealand. The company earns money the old-fashioned way: train the recommender, charge a premium for the science, and rely on professional endorsement to drive repeat purchases.

FY25 marked a genuine milestone — the first profitable year in the company's history. Revenue grew 42% to $18.4 million, gross margins held above 61%, and adjusted EBITDA reached $0.93 million. International revenue, while small at $1.49 million, grew 69% and gives the business a credible second act.

The investment case rests on whether operating leverage can drive margins from 5% toward 15% as revenue scales — and whether international markets deliver before domestic competition intensifies. Both are plausible. Neither is certain. Blackmores is watching the practitioner channel, clinical advantages have a shelf life of three to five years, and working capital is still consuming cash despite accounting profitability.

At A$0.43 versus our fair value of A$0.229, the stock is overvalued by 88%.

What happened?

FY25 delivered the inflection point management had been working toward. Revenue of $18.4 million was up 42%, driven by same-store pharmacy growth of 75% and a 69% surge in international revenue. Gross margins held at 61%, reflecting the premium the clinical evidence supports. Adjusted EBITDA turned positive for the first time at $0.93 million, though free cash flow remained negative at -$1.3 million as inventory expanded 117% — a deliberate build ahead of international shipments, but a drag on cash nonetheless.

What's next?

The near-term story is margin expansion. With a largely fixed education infrastructure and a $8 million cost base, each additional dollar of revenue drops through at high contribution margins. We forecast EBITDA margins doubling to 10% by FY26, then reaching 15% by FY28 — the ceiling we consider sustainable before competitive pressure sets in.

International markets are the wildcard. Distribution partners in Ireland, Canada, and New Zealand provide shelf access, but converting access into profitable volume typically takes two to three years. Three clinical trials due for completion — covering mental health, bone density, and paediatric immunity — could accelerate professional uptake if results are positive. Working capital normalisation is a quieter but equally important milestone: until inventory turns improve, cash generation will lag reported earnings.

The single biggest risk is not operational — it is valuation. To justify A$0.43, the market must believe BIO will sustain 40%+ revenue growth and achieve EBITDA margins above 20%. Our analysis caps sustainable margins at 15%, the point beyond which competitive response from Blackmores and others becomes economically rational. Margin assumptions above that ceiling are structurally unsound, not just optimistic. Even if management executes its international expansion flawlessly and domestic market share continues to build, our bull case scenario produces A$0.385 — still 11% below today's price. There is no credible scenario in our model where the current price is fair. The practical trigger for reassessment is a correction toward A$0.25–0.30, where the growth story starts to carry a reasonable price tag.